endpts.com

GENERAL
META
HTML
LINK ANALYSIS
SERVER
IP

Endpts.com recives any estimated n/a unique visitors and n/a unique page views per day. Revenue gained from these much visits may be n/a per day from various advertising sources. The estimated worth of site is n/a.

Website Age n/a
Alexa Rank no-data
Country United States
IP Address 35.196.185.211

META INFORMATION

Title

Endpoints News – The biopharma world is here

Description

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width, initial-scale=1, maximum-scale=1

google ads

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 12.34 %

endpts.com has a website text/code ratio of 12.34 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

H10
H225
H360
H40
H50
H60

No	Text
1	Updated: legend fetches $424 million, emerges as biggest winner yet in pandemic ıpo boom as shares soar
2	Covid-19 roundup: abbvie jumps into covid-19 antibody hunt; astrazeneca shoots for 2b doses of oxford vaccine — ...
3	Ra capital, hillhouse join $310m rush to back everest's climb to commercial heights in china
4	Merck wins a third fda nod for antibiotic; mereo tackles tıgıt with $70m raise in hand
5	ıs a powerhouse merck team preparing to leap past roche — and leave gilead and bristol myers behind — in the race ...
6	Macrogenics ceo scott koenig gets the pre-asco party started with some encouraging pipeline tidbits — leaving lots ...
7	Dealmaking spiked to record levels in april as covid-19 triggered a fever of partnering. but what happens to ...
8	Full steam ahead, pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare ...
9	Atlas raises new $400m fund amid spree of vc raises. here’s what they’ll spend it on
10	Covid-19 roundup: moderna readies to enter phııı in july, astrazeneca not far behind; eu ready to negotiate vaccine ...
11	Covid-19 roundup: barda supports operation warp speed with big $628m contract to service america's vaccine production ...
12	Fda delays decision on novartis’ potential blockbuster ms drug, wiping away priority review
13	The 20 under 40: ınside the next generation of biopharma leaders
14	Here are the 52 new drugs approved by the fda in 2019. who won? who lost? and who just survived to 2020?
15	Special report: twenty extraordinary women in biopharma r&d who worked their way to the top
16	[video] celebrating trial failures, changing the culture and allying with california dreamers: r&d chief hal barron ...
17	Can a small biotech successfully tackle an everest climb like alzheimer’s? athira has $85m and some influential backers ready to give it a shot
18	Gsk presents case to expand use of its lupus drug in patients with kidney disease, but the field is evolving. how ...
19	Updated: estimating a us price tag of $5k per course, remdesivir is set to make billions for gilead, says key analyst
20	A low-profile biotech bests regeneron in high-profile patent suit
21	Pfizer, merck kgaa cement bavencio bladder cancer win with os data — while carving another niche in rare cancer
22	Capitalizing pablo: the world’s biggest drug royalty buyer is going public. and the low-key ceo divulges a few ...
23	Covid-19 roundup: did insiders cash in on positive news report about gilead before publication?
24	Caught in a standoff with its contract manufacturer over covid-19 vaccine, ınovio files suit in an attempt to break ...
25	Stephen hahn: fda will make some changes amid covid-19 permanent

No	Text
1	Top stories
2	Latest (2)
3	Updated: white house names finalists for operation warp speed — with 5 expected names and one notable omission
4	As it happened: a bidding war for an antibiotic maker in a market that has ravaged its peers
5	David chang steps up to ceo spot at wuxi's cell and gene therapy cdmo; david meline is the new cfo at moderna
6	Moderna’s new cfo took a cut in salary to jump to the mrna revolutionary. but then there’s the rest of the ...
7	Portion of neil woodford’s remaining investments, including nanopore, sold off for $284 million
8	Drug manufacturing giant lonza taps roche/pharma ‘reinvention’ vet as its new ceo
9	Amgen vet david meline finds a new cfo roost at moderna, taking a ride on the covid-19 tiger as departing exec cashes ...
10	Cameron durrant hustled his way from the otc sidelines right into the covid-19 drug race. death or glory lies ...
11	Why merck waited, and what they now bring to the covid-19 fight
12	ıpos abound in the time of coronavirus, as forma therapeutics pencils in $150m nasdaq debut
13	Versant-backed, bristol myers-stamped repare therapeutics guns for $100m ıpo
14	For a post-soliris world, atlas-backed q32 bio outlines $46m next-gen complement play
15	Bristol myers is cleaning up the post-celgene merger pipeline, and they’re sweeping out an experimental checkpoint ...
16	José baselga finds promise in new cla*** of rna-modifying cancer targets, locking in 3 preclinical programs with $55m
17	Once a high flyer, a staggering aduro is auctioning off most of the pipeline as ceo stephen ısaacs hands off the ...
18	Bullish biotech market propels pliant to $144m ıpo — as novartis provides a $10m boost
19	The big money: poised to make drug r&d history, a china biotech unveils unicorn racing ambitions in a bid to raise ...
20	As biotech ıpos sizzle on virtual wall street, 3 new players roll the dice on megamoney gambles topping $325m
21	Premium stories see all
22	Don't miss see all
23	Endpoints standouts
24	Peer review see all
25	Sierra oncology brings on former aimmune ceo to the helm; flags***p woos ex-novartis exec fabrice chouraqui
26	Sanofi brings in 4 new executives in continued shake-up, as vaccines and consumer health chief head out the door
27	Looking to move past an r&d fiasco, ıpsen poaches their new ceo from sanofi
28	The man who led gilead’s autoimmune pivot heads to boston; novartis gets a new chief for its aı ınnovation center
29	Cherry thomas joins caribou as svp of clinical development; artax locks in joseph lobacki as ceo
30	R&d channel feed
31	Gilead bolsters its case for blockbuster hopeful filgotinib as fda ponders its decision
32	New safety data expose potential weakness as pfizer's abrocitinib takes on dupixent in eczema
33	Bristol myers squibb's just-launched ms drug zeposia makes the cut in key ulcerative colitis trial
34	Novus therapeutics plunges deep into penny stock territory after failed ear trial
35	Gilead releases another round of murky remdesivir results
36	Pharma channel feed
37	Bristol myers squibb finally gets in the frontline nsclc game dominated by merck, adding a second opdivo/yervoy-based option
38	German merck bests us merck in uk copyright tussle of merck v. merck
39	Fda approves the first generic for amarin's vascepa — but is a fish oil price war imminent?
40	Parkinson's patients no longer need to rely on a needle for apomorphine antidote for 'off' episodes after new fda approval
41	Once valued at $4b, an embattled akorn — nursing a market cap of roughly $37m — files for bankruptcy
42	Coronavirus channel feed
43	Novartis jumps into covid-19 vaccine hunt, as big pharma and big biotech commit to billions of doses
44	Covid-19 roundup: fda's stephen hahn personally helped a doctor set up hydroxychloroquine trial — report
45	Fda explains impact of covid-19 on applications, formal meetings
46	Venrock survey shows growing recognition of coronavirus toll, waning confidence in arrival of vaccines and treatments
47	Covid-19 roundup: buoyed by soaring shares, novavax inks a $167m deal to buy covid-19 vaccine-making facility; france cools on hydroxychloroquine
48	Channels
49	More
50	Work in biotech
51	Sign in to your account
52	E-mail
53	Pa***word
54	Request magic link
55	Email (2)
56	Reset pa***word
57	About you
58	Subscriptions

Text Styling

STRONG0
B2
EM1
I0
U0
CITE0

No	Text
1	magic link that lets you sign in quickly without using a pa***word
2	one-time use only

No	Text
1	all

LINK ANALYSIS

Total Link Count: 213

Internal Link Count : 197

No	Text	Type
1	-	empty
2	All News	text
3	Premium Stories	text
4	Coronavirus	text
5	R&D	text
6	Pharma	text
7	Venture	text
8	People	text
9	Startups	text
10	Regulatory	text
11	Deals	text
12	IPOs	text
13	China	text
14	Cell/Gene Tx	text
15	Bioregnum	text
16	Peer Review	text
17	Discovery	text
18	Outsourcing	text
19	In Focus	text
20	AI	text
21	Special	text
22	Sponsored Posts	text
23	Biotech Voices	text
24	About Us	text
25	SUBSCRIBE	text
26	-	empty
27	UPDATED: Legend fetches $424 million, emerges as biggest winner yet in pandemic IPO boom as shares soar	text
28	IPOs	text
29	R&D	text
30	-	empty
31	Covid-19 roundup: AbbVie jumps into Covid-19 antibody hunt; AstraZeneca shoots for 2B doses of Oxford vaccine — ...	text
32	Coronavirus	text
33	-	empty
34	RA Capital, Hillhouse join $310M rush to back Everest's climb to commercial heights in China	text
35	Venture	text
36	China	text
37	-	empty
38	Merck wins a third FDA nod for antibiotic; Mereo tackles TIGIT with $70M raise in hand	text
39	Protocols	text
40	UPDATED: White House names finalists for Operation Warp Speed — with 5 expected names and one notable omission	text
41	Coronavirus	text
42	As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers	text
43	R&D	text
44	David Chang steps up to CEO spot at WuXi's cell and gene therapy CDMO; David Meline is the new CFO at Moderna	text
45	Peer Review	text
46	Moderna’s new CFO took a cut in salary to jump to the mRNA revolutionary. But then there’s the rest of the ...	text
47	People	text
48	Portion of Neil Woodford’s remaining investments, including Nanopore, sold off for $284 million	text
49	Venture	text
50	Deals	text

External Link Count : 16

No	Text	Type
1	Calendar	text
2	Biopharma Jobs	text
3	Webinars	text
4	Events	text
5	Advertise	text
6	Privacy Policy	text
7	reported	text
8	-	empty
9	-	empty
10	Events	text
11	Webinars	text
12	Calendar	text
13	Advertise	text
14	Endpoints Careers	text
15	Advertise	text
16	Privacy Policy	text